BeOne Innovation Center and Voyagers Capital Launch Fund – Early-Stage Drug Investment Vehicle Targets Guangzhou Biotech
The BeOne Innovation Center (BIC) and Voyagers Capital jointly announced the establishment of the “BeOne...
BeOne Medicines
BeOne Medicines Reports $5.3B Full‑Year Revenue – Brukinsa Drives 40% Growth, 2026 Guidance Raised
BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced Q4 and full‑year 2025 financial results, with global...
BeOne’s Sonrotoclax Wins Conditional NMPA Approval for BCL-2 Inhibitor in CLL/SLL and MCL
BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that its self‑developed Class 1 innovative drug...
BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer
BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that the U.S. Food and Drug...
BeOne Medicines Names Dual Presidents in Leadership Overhaul
BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced a leadership restructuring, appointing Dr. Lai...
BeOne’s Sotoclax Wins FDA Priority Review for Mantle Cell Lymphoma
BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that the U.S. FDA has accepted its...
BeOne’s Zanidatamab Achieves PFS & OS Wins in HERIZON-GEA-01 Phase 3 HER2-Positive Cancer Trial
BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced its HER2‑targeted bispecific antibody zanidatamab (Ziihera)...
BeOne Medicines Posts $1.4 B Q3 2025 Revenue, Driven by BRUKINSA Momentum
BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) released its third‑quarter 2025 financial results, reporting...
BeOne Medicines Receives FDA Breakthrough Therapy Designation for Sonrotoclax in Relapsed Mantle Cell Lymphoma
BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that the U.S. Food...
BeOne Medicines Terminates Patent Dispute with AbbVie’s Pharmacyclics Over BTK Inhibitors
BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that it has terminated...
BeOne Secures $950 M Deal with Royalty Pharma for Tarlatamab Rights
On August 26, 2025, BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced that it had...
BeOne Medicines Reports 42% Revenue Growth in Q2 2025 Driven by Brukinsa Sales
BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced its financial results and business...
BeOne Medicines’ BGB-16673 Granted PRIME Designation by EMA for Waldenström’s Macroglobulinemia
China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced on July 31, 2025,...
BeOne Medicines’ Tislelizumab Receives Positive CHMP Opinion for NSCLC Treatment
China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that its PD-1 antibody...
BeOne Medicines’ Tevimbra Approved by European Commission for Nasopharyngeal Carcinoma
China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that it has received...
Biocytogen and BeOne Medicines Deepen Partnership with Global Antibody Licensing Agreement
China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has announced a global antibody molecule licensing...
EMA Panel Recommends Brukinsa Tablet Formulation for Approval
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
BeOne Medicines Launches Ziihera for HER2-High Biliary Tract Cancer in China
China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced the official commercial availability...
Takeda’s Shan Guohong Departs to Join BeOne Medicines as Next Career Move
Shan Guohong, Global Senior Vice President of Takeda Pharmaceutical (TYO: 4502) and President of Takeda...
BeOne Medicines Wins FDA Approval for Brukinsa Tablet Across All Five Indications
China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that it has received...